Bioventus Inc. (NYSE:BVS) Director John A. Bartholdson Acquires 178,998 Shares of Stock

Posted by on May 24th, 2023

Bioventus Inc. (NYSE:BVS – Get Rating) Director John A. Bartholdson bought 178,998 shares of the firm’s stock in a transaction on Monday, May 22nd. The shares were purchased at an average cost of $2.08 per share, with a total value of $372,315.84. Following the transaction, the director now directly owns 5,909,136 shares in the company, valued at approximately $12,291,002.88. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Bioventus Stock Performance

Shares of BVS opened at $2.43 on Wednesday. The company has a market cap of $189.66 million, a PE ratio of -0.52 and a beta of 0.28. The company has a current ratio of 1.57, a quick ratio of 1.13 and a debt-to-equity ratio of 1.68. The stock has a 50-day moving average price of $1.22 and a 200-day moving average price of $1.92. Bioventus Inc. has a 12-month low of $0.80 and a 12-month high of $10.02.

Bioventus (NYSE:BVS – Get Rating) last released its earnings results on Friday, March 31st. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.11). Bioventus had a positive return on equity of 0.49% and a negative net margin of 55.77%. The firm had revenue of $125.83 million during the quarter, compared to the consensus estimate of $134.09 million. As a group, equities analysts forecast that Bioventus Inc. will post -0.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bioventus

Several hedge funds have recently made changes to their positions in BVS. Ameriprise Financial Inc. purchased a new stake in Bioventus in the first quarter worth $35,000. SkyView Investment Advisors LLC bought a new position in shares of Bioventus during the first quarter valued at $54,000. Geode Capital Management LLC lifted its holdings in Bioventus by 2.3% in the first quarter. Geode Capital Management LLC now owns 637,103 shares of the company’s stock valued at $682,000 after acquiring an additional 14,456 shares during the period. Two Sigma Advisers LP bought a new position in Bioventus in the first quarter valued at about $37,000. Finally, Two Sigma Investments LP lifted its holdings in Bioventus by 357.1% in the first quarter. Two Sigma Investments LP now owns 130,314 shares of the company’s stock valued at $139,000 after acquiring an additional 101,805 shares during the period. 46.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum cut their target price on Bioventus from $10.00 to $5.00 and set a “hold” rating on the stock in a report on Monday, April 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bioventus currently has a consensus rating of “Hold” and a consensus target price of $5.50.

Bioventus Company Profile

(Get Rating)

Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.

Featured Stories

Insider Buying and Selling by Quarter for Bioventus (NYSE:BVS)

Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.